Evidence map›Paper›PMID 35890048›Full record

ArticlePathogens (Basel, Switzerland)2022

Improving Drug Sensitivity of HIV-1 Protease Inhibitors by Restriction of Cellular Efflux System in a Fission Yeast Model.

Jiantao Zhang, Qi Li, Shigehiro A Kawashima, Mohamed Nasr, Fengtian Xue, Richard Y Zhao

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jiantao ZhangDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-2875-9743
Qi LiDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Shigehiro A KawashimaGraduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
Mohamed NasrDrug Development and Clinical Sciences Branch, Division of AIDS, NIAID, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3322-3716
Fengtian XueDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
Richard Y ZhaoDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-3424-2852
University of Maryland, Baltimore · USNational Institutes of Health · USThe University of Tokyo · JP

Funding

A Novel and High Throughput System for Drug Discovery and Testing on Multidrug Resistant HIV-1 ProteasesR01GM127212 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ZHAO, RICHARD YUQI · 2017 to 2018
$603k
Rapid Phenotyping of the ZIKV GenomeR21AI129369 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ZHAO, RICHARD YUQI · 2017 to 2018
$425k
A Novel and High Throughput System for Drug Discovery and Testing on Multidrug Resistant HIV-1 ProteasesR01AI150459 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ZHAO, RICHARD YUQI · 2019 to 2019
$301k
Fission Yeast as a HTS Platform for New Molecular Probes of HIV-1 VPR-Medicated AR21NS063880 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI ZHAO, RICHARD YUQI · 2008 to 2010
$188k
Viral Protein R (Vpr) in HIV-associated Brain Neuroinflammation and NeurotoxicityI01BX004652 · VA · BALTIMORE VA MEDICAL CENTER · PI J. Marc Simard, RICHARD YUQI ZHAO · 2020 to 2026
–
BLRD VA I01 BX004652National Institute of Allergy and Infectious Diseases R01 GM127212/AI150459NIAID NIH HHS R01 AI150459NIAID NIH HHS R21 AI129369NIGMS NIH HHS R01 GM127212NINDS NIH HHS R21 NS063880United States Department of Veterans Affairs I01BX004652
6 · The paper itself

Abstract

Fission yeast can be used as a cell-based system for high-throughput drug screening. However, higher drug concentrations are often needed to achieve the same effect as in mammalian cells. Our goal here was to improve drug sensitivity so reduced drugs could be used. Three different methods affecting drug uptakes were tested using an FDA-approved HIV-1 protease inhibitor (PI) drug Darunavir (DRV). First, we tested whether spheroplasts without cell walls increase the drug sensitivity. Second, we examined whether electroporation could be used. Although small improvements were observed, neither of these two methods showed significant increase in the EC

Indexed as

ABC and MFS transportersdrug efflux pumpselectroporationfission yeast (Schizosaccharomyces pombe)human immunodeficiency virus type 1 (HIV-1)protease inhibitor (PI) drugsprotease (PR)small molecule drug uptakespheroplasts

Identifiers

PMID35890048
PMCPMC9318301
OpenAlexW4285732622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.